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Abstract
Background: Rapid demographic ageing is a growing public health issue in many low- and middle-income countries
(LAMICs). Mild cognitive impairment (MCI) is a construct frequently used to define groups of people who may be at risk of
developing dementia, crucial for targeting preventative interventions. However, little is known about the prevalence or
impact of MCI in LAMIC settings.
Methods and Findings: Data were analysed from cross-sectional surveys established by the 10/66 Dementia Research
Group and carried out in Cuba, Dominican Republic, Peru, Mexico, Venezuela, Puerto Rico, China, and India on 15,376
individuals aged 65+ without dementia. Standardised assessments of mental and physical health, and cognitive function
were carried out including informant interviews. An algorithm was developed to define Mayo Clinic amnestic MCI (aMCI).
Disability (12-item World Health Organization disability assessment schedule [WHODAS]) and informant-reported
neuropsychiatric symptoms (neuropsychiatric inventory [NPI-Q]) were measured. After adjustment, aMCI was associated
with disability, anxiety, apathy, and irritability (but not depression); between-country heterogeneity in these associations
was only significant for disability. The crude prevalence of aMCI ranged from 0.8% in China to 4.3% in India. Country
differences changed little (range 0.6%–4.6%) after standardization for age, gender, and education level. In pooled estimates,
aMCI was modestly associated with male gender and fewer assets but was not associated with age or education. There was
no significant between-country variation in these demographic associations.
Conclusions: An algorithm-derived diagnosis of aMCI showed few sociodemographic associations but was consistently
associated with higher disability and neuropsychiatric symptoms in addition to showing substantial variation in prevalence
across LAMIC populations. Longitudinal data are needed to confirm findings—in particular, to investigate the predictive
validity of aMCI in these settings and risk/protective factors for progression to dementia; however, the large number
affected has important implications in these rapidly ageing settings.
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Ageing [1] and the health transition in low- and middle-income
countries (LAMICs) are responsible for an unprecedented increase
in the prevalence and societal impact of noncommunicable
diseases, including dementia [2]. Large numbers of people with
dementia currently live in LAMICs [3,4] with prevalence
estimates comparable to those of the Western world [5]. At
present, disease-modifying drugs are not available [6] and
symptomatic medications have been found to have only modest
benefit [7]. Primary prevention of dementia is therefore of great
importance [8].
Mild cognitive impairment (MCI) is an intermediate state
between normal cognitive ageing and dementia [9]. Identification
of MCI is thought to be crucial to early intervention. Indeed, in
some studies MCI is associated with an increased risk of dementia
[10], as well as with future disability [11] and mortality [12]. Such
associations, however, do vary according to the nature of the
sample (clinical versus population-based), the case definition of
MCI applied, the assessment procedures used for operationalizing
component criteria [13–15], and, potentially, the cultural
background of participants [16,17]. A recent review also suggested
that MCI is associated with neuropsychiatric symptoms, cited as
being of potential importance for defining subgroups at higher risk
of developing dementia in the future [18].
In community-dwelling older adults the prevalence of amnestic
MCI (aMCI), defined according to Petersen’s revised criteria [10],
ranges between 2.1% [19] and 11.5% [20] and is most commonly
found to be around 3%–5% [21–33] with few exceptions in older
samples [20,34–36]. Reports of the community prevalence of
aMCI have been predominantly derived from European and
North American populations. To our knowledge, very few
population-based studies have been published from LAMICs
and those from Asia are controversial. Specifically, estimates of
aMCI prevalence were similar to those found in Western countries
in Kolkata, India (6%) [37] and in Chongqing, China (4.5%) [29],
but higher prevalences were reported by Lee and colleagues in
Malaysia (15.4%) [38] and by Kim et al. in South Korea (9.7%)
[39].
Estimating the population prevalence of MCI in LAMICs is a
public health priority as rapid demographic ageing is predicted to
result in a large majority of people residing in these regions being
at risk of dementia and cognitive decline. If so, this will have
significant implications with regard to social support and future
health care costs, especially as systems are not in place to cope with
increased neurodegenerative disease and health resources at
present are already extremely limited.
In this study, using data from the cross-sectional phase of the
10/66 Dementia Research Group (DRG) programme on
dementia, noncommunicable diseases and ageing in LAMICs
[40], we operationalized the Mayo Clinic–defined aMCI [10]
construct and then estimated the prevalence of this condition in
eight LAMICs, in addition to its sociodemographic correlates and
associations with disability and neuropsychiatric symptoms.
Methods
Ethics Statement
Written informed consent, or witnessed oral consent in case of
illiteracy, or next of kin written agreement in case of incapacity,
was obtained from all participants. The appropriate Research
Ethics Committees at King’s College London and at all local
countries approved the study protocol and the consent procedures.
Sample
The 10/66 study has been described previously [40]. In brief,
the study consisted of a series of cross-sectional one-phase
geographic catchment area surveys, carried out in eight urban
and rural sites in Peru, Mexico, China, and India, and in three
urban sites in Cuba, the Dominican Republic, and Venezuela,
between January 2003 and November 2007. The target sample
size was 2,000 participants per country, in order to allow
estimation of a typical dementia prevalence of 4.5% (SE 0.9%)
with 80% power. All community-resident individuals aged 65+ y
were eligible for inclusion. Using a process of full household
enumeration, all residents aged 65+ y within catchment areas were
approached by means of door-knocking and a reliable informant
was required for inclusion. Being younger than 65 y was the only
exclusion criteria, and weighted sampling procedures were not
applied.
Measurements
All participants completed the 10/66 standardized assessment at
their place of residence. This consisted of participant and
informant interviews and a physical examination, described in
full elsewhere in an open-access publication [40]. Participant
interviews included questionnaire measures of sociodemographic
status, education and childhood environment, social networks and
support, self-report measures of common physical disorders, health
service use, and lifestyles (smoking, alcohol intake, diet, exercise),
in addition to a fully structured diagnostic interview for mental
disorder (Geriatric Mental State [GMS], described below).
Physical examinations included measures of resting blood
pressure, anthropometric measures, and a structured neurological
examination. A battery of cognitive assessments was administered
(described below) and an informant interview included structured
questionnaires on cognitive decline and neuropsychiatric symp-
toms (both described below), as well as questions on care
arrangements, caregiver strain and distress, financial implications
of caregiving, and support received. The 10/66 study protocol was
translated into Spanish, Tamil, and Mandarin, and minor
adaptations were made by local clinicians fluent in English.
Validation statistics for the assessments and procedures have been
published [41]. The protocol included the GMS Examination
[42,43], an informant interview on all participants, a neurological
examination, and a neuropsychological battery that comprised the
following:
(1) The participant interview section of the Community
Screening Instrument for Dementia (CSI ‘‘D’’) [44]. This was
developed as a screening instrument for dementia for use in cross-
cultural settings in combination with the informant interview. The
cognitive assessment covers multiple domains, including orienta-
tion to time and place, language, memory, praxis, and abstract
thinking. It deliberately excludes literacy-dependent items. A
memory subscale was derived from the CSI ‘‘D’’ using the items
addressing immediate and delayed recall of a three word list, recall
of the name of the interviewer, and recall of five elements of a
short story (logical memory). (2) The Modified Consortium to
Establish a Registry for Alzheimer’s Disease (CERAD) ten-word-
list learning task [45]. Six words: butter, arm, letter, queen, ticket,
and grass were taken from the original CERAD battery English
language list. Pole, shore, cabin, and engine were replaced with
corner, stone, book, and stick, which were deemed more culturally
appropriate for all sites in the 10/66 pilot phase (a wider sample
that included the survey sites). In the learning phase, the list is read
to the participant. Next, the participant is asked to immediately
recall the words that they remember. This process is repeated
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maximum total of 30. After a 5-min delay, the participant is again
asked to recall the ten words with encouragement but no cues,
giving a word list delayed recall score with a maximum total score
of 10.
Demographic correlates analyzed against aMCI were age,
gender, education, and number of assets. Participants’ gender and
stated age were recorded. Age was confirmed by the interviewer
from official documentation and informant report, and any
discrepancies resolved through further questions and clarification
and, ultimately, by consensus within the research team. Illiteracy
(inability to read and/or write), level of education (none/did not
complete primary/completed primary/secondary/tertiary), and
number of household assets (car, television, refrigerator, telephone,
plumbed toilet, water, and electricity mains) were also recorded.
The impact of aMCI was quantified through investigating
associations with disability and neuropsychiatric symptoms.
Participant interviews included the 12-item WHO disability
assessment schedule (WHODAS-12) [46], which assesses five
activity-limitation domains (communication, physical mobility,
self-care, interpersonal interaction, life activities and social
participation). Two questions with scores ranging from 0 (no
difficulty) to 4 (extreme difficulty) cover each domain, and the
global standardized score ranges from 0 (not disabled) to 100
(maximum disability). Details on the WHODAS 2.0 validity and
psychometric properties can be found elsewhere [47,48]. The
informant interview, as well as administering structured CSI ‘‘D’’
questions (regarding decline in memory or intelligence, activities of
daily living, social and occupational functioning used for dementia
diagnoses—summarized below and applied as an exclusion
criteria), also included the neuropsychiatric inventory (NPI-Q)
[49], and the following binary symptom categories were selected
for analyses of associations with aMCI: depression, anxiety,
apathy, irritability.
For analyses of associations of aMCI with disability and
neuropsychiatric symptoms, the following covariates available in
the dataset were used for adjusted models in addition to the four
sociodemographic variables described above: depression (GMS),
self-reported limiting physical impairments (arthritis, visual
difficulties, hearing difficulties, respiratory disorders, heart prob-
lems, gastrointestinal problems, fainting episodes, limb paralysis,
skin disorders), self-reported hypertension, self-reported stroke,
psychotic disorder (GMS), self-reported regular pain.
Case Definition of aMCI
Mayo Clinic–defined aMCI was diagnosed on the basis of the
following criteria: (1) objective memory impairment beyond that
expected for age; (2) subjective memory complaint; (3) no, or only
mild impairment in core activities of daily living, and (4) no
dementia. Each criterion was operationalized as follows.
Objective memory impairment. A composite memory
score was created using results from the memory subscale of the
CSI ‘‘D’’ [44], immediate and delayed word recall scores from the
modified CERAD ten-word list [50]. For all tasks impaired
performance was defined as a score 1.5 standard deviation (SD) or
more below the mean adjusted for age and education. The 1.5-SD
definition stems from that applied to define ‘‘abnormal memory
performance’’ by Peterson et al. in 1999 [9], and has been recently
recommended also by a National Institute on Aging-Alzheimer’s
Association workgroup [51]. Operationalization of MCI in other
population-based studies has consistently followed this definition
[25,33,52,53], which has also been used to define other constructs
such as ‘‘Cognitive Impairment No Dementia’’ [54]. The CERAD
word list has been used in previous research [25]. Although, there
have been controversies surrounding the MCI entity itself [55–58],
they have not to our knowledge focused on the 1.5-SD threshold.
Norms were derived from controls without dementia from the 24-
centre 10/66 pilot study, which had found minimal geographic
variation [41]. Participants were excluded if hearing impairment
had prevented cognitive assessment.
Subjective memory impairment. An ordinal scale ranging
from 0 to 6 was created by summing item scores from relevant
questions in the GMS including: (1) Have you had any difficulty
with your memory (0, no; 1, yes)? (2) Have you tended to forget
names of your family or close friends/where you have put things
(for each question: 0, no/transient; 1, noticed most days per week;
2, noticed daily)? (3) Do you have to make more efforts to
remember things than you used to (0, no; 1, yes)? Using this scale,
subjective memory impairment was defined as present when an
individual scored three or more: the definition that has been used
in all previous research to use this scale [59,60].
Normal activities of daily living/instrumental activities
of daily living. On the basis of responses from the CSI ‘‘D’’
informant interview, normal activities of daily living (ADL)/
instrumental activities of daily living (IADLs) were defined as very
mild or no impairment in either carrying out household chores,
pursuing hobbies, using money, feeding, dressing, or toileting. The
definition of impairment did not include problems arising only
from physical impairments.
No dementia. Diagnoses of dementia were applied using the
10/66 dementia algorithm and Diagnostic and Statistical Manual
of Mental Disorders IV (DSM-IV) criteria [61]. Participants
meeting either criterion were excluded from the analyzed sample
(both aMCI cases and controls).
Statistical Analysis
Analyses were carried out on the 10/66 data archive release 2.1.
All analyses used STATA version 10.1 [62]. As mentioned above,
participants with dementia were excluded from all analyses as has
been standard practice in MCI epidemiological research. Sample
characteristics across countries were described including age,
gender, education, number of household assets, global disability
scores (WHODAS-12) [46], and NPI-Q symptoms [49].
In order to determine the potential impact of aMCI we assumed
that, while both activities of daily living (ADLs) and instrumental
activities of daily living (IADLs) would be expected to be intact in
people with aMCI, subtle functional impairment may already be
present as well as possibly nonspecific and mild behavioral and
psychological symptoms of dementia (BPSD) [18]. Zero-inflated
negative binomial regression (ZINB) count models were used to
assess the association between aMCI and WHODAS-12 disability
and NPI-Q scores using identical models to those previously
reported for these samples [63]. We used zero-inflated models to
deal with skewness in the distribution of the scores characterized
by excessive zeros (inflation). The model distinguishes a group
whose members have always zero counts (referred to as ‘‘certain
zero’’), from one in which members have either zero or positive
counts. ZINB includes a logistic part to model the probability that
a zero comes from the first group versus the second group and a
negative binomial part to model the counts within the second
group. Log-scale coefficients were exponentiated and 95%
confidence intervals back-transformed. We determined the
appropriateness of the ZINB model against a standard negative
binomial model using the Vuong test postestimation and adjusted
for the relevant covariates listed above, followed by Poisson
regression models to generate prevalence ratios for NPI-Q
symptoms as binary-dependent variables. ZINB models were
further compared to zero-inflated Poisson models and in every
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Stata and theta by some other sources) was significant at the 0.001
level, indicating ZINB as more appropriate in all cases.
Behavioural/psychological outcomes, depression, anxiety, apathy,
irritability were modelled separately against aMCI as an
independent variable for illustrative purposes, with no attempt to
adjust given symptoms for the other three, accepting that these are
related constructs.
Prevalence of aMCI was reported for each country by age and
gender and adjusted for household clustering. Direct standardiza-
tion, using the whole sample as the reference population, was used
to compare prevalence estimates across countries after adjustment
for age, gender, and education. For each country associations with
age (continuous variable), gender, education (ordinal variable), and
number of household assets (ordinal variable) on aMCI prevalence
were calculated using mutually adjusted (as appropriate) preva-
lence ratios (PRs), with robust 95% confidence intervals (using the
‘‘robust’’ syntax in Stata to take into account household clustering:
model robust standard errors [64,65]), using Poisson working
models.
To determine the pooled effects for all analyses, the statistical
outputs for each country were combined into fixed-effect meta-
analyses. Random effect models were not used as we wished to
summarise the countries within this study rather than generalise to
a hypothetical population of centres. We then calculated Cochrane
Q heterogeneity and Higgins’ I
2 (95% CIs). The latter statistics set
the degree of heterogeneity between studies that is not explained
by chance and is expressed as a percentage with values up to 25%,
50%, and over 75% representing mild, moderate, and high
heterogeneity, respectively [66].
Results
The results were derived from a total of 15,376 participants
aged 65+ and without dementia across the different countries.
Response rates (i.e., participation rates for all potentially eligible
residents within the defined geographic catchments) were higher
than 80% in all countries. Missing data on the variables of interest
were present in less than 1% of the sample. Descriptive data by
country are displayed in Table 1. Age was not evenly distributed
across groups (65–69, 70–74, 75–79, and 80+ y) across countries,
the samples from Venezuela, China, and India being slightly
younger. In all countries more women participated than men.
Educational level was highest in Cuba, and the number of
household assets was lowest in Mexico and India.
In each country there was a statistically significant zero-inflation
in the distributions of WHODAS-12 scores (Vuong test for the
whole sample, z=45.29, p,0.001) that confirmed the better fit of
ZINB over negative binomial alone. Associations between aMCI,
disability, and neuropsychiatric symptoms are summarized in
Table 2 along with meta-analytical fixed-effect method-pooled
estimates, and between-country heterogeneity. After adjustment,
Table 1. Sociodemographic characteristics of participants by country.
Characteristics Cuba
Dominican
Republic Peru Venezuela Mexico China India Puerto Rico
Sample size (n) 2,620 1,767 1,767 1,820 1,821 2,014 1,802 1,765
Response rate (%) 94 95 82 80 85 83 83 93
Age, n (%) – M V 7 0 141040
65–69 y 738 (28.2) 511 (28.9) 538 (30.5) 813 (44.7) 537 (29.5) 683 (33.9) 703 (39.0) 398 (22.6)
70–74 y 739 (28.2) 483 (27.3) 475 (26.9) 450 (24.7) 552 (30.3) 634 (31.5) 604 (33.5) 439 (24.9)
75–79 y 582 (22.2) 345 (19.5) 368 (20.8) 320 (17.6) 384 (21.1) 417 (20.7) 290 (16.1) 436 (24.7)
80+y 555 (21.2) 428 (24.2) 386 (21.8) 236 (13.0) 348 (19.1) 280 (13.9) 201 (11.2) 492 (27.9)
Gender – M V 0 2 03 3 001 5 7
Females, n (%) 1,686 (64.4) 1,154 (65.3) 1,073 (60.7) 1,146 (63.0) 1,143 (62.8) 1,128 (56.0) 974 (54.0) 1,183 (67.0)
Educational level, n (%) – MV 8 19 16 40 2 0 2 0
No education 54 (2.1) 314 (17.8) 103 (5.8) 133 (7.3) 459 (25.2) 743 (36.9) 935 (51.9) 47 (2.7)
Some education 548 (20.9) 916 (51.8) 212 (12.0) 408 (22.4) 802 (44.0) 246 (12.2) 411 (22.8) 313 (17.7)
Complete primary 864 (33.0) 338 (19.1) 654 (37.0) 913 (50.2) 337 (18.5) 532 (26.4) 301 (16.7) 356 (20.2)
Complete secondary 681 (26.0) 126 (7.1) 486 (27.5) 262 (14.4) 117 (6.4) 358 (17.8) 110 (6.1) 661 (37.5)
Complete tertiary 468 (17.9) 66 (3.7) 301 (17.0) 92 (5.1) 104 (5.7) 135 (6.7) 43 (2.4) 383 (21.7)
Three assets or fewer – M V 8 5 000140
n (%) 67 (2.6) 256 (14.5) 83 (4.7) 33 (1.8) 373 (20.5) 104 (5.2) 918 (51.0) 4 (0.2)
Neuropsychiatric symptoms, n (%) 41 20 11 103 16 3 29 112
Depression 117 (4.5) 220 (12.5) 86 (4.9) 84 (4.6) 73 (4.0) 3 (0.2) 139 (7.7) 36 (2.0)
Anxiety 158 (6.0) 233 (13.2) 199 (11.3) 263 (14.5) 121 (6.6) 7 (0.4) 77 (4.3) 101 (5.7)
Apathy 117 (4.5) 226 (12.8) 93 (5.3) 138 (7.7) 165 (9.1) 15 (0.7) 18 (1.0) 58 (3.5)
Irritability 583 (22.5) 412 (23.3) 381 (21.6) 383 (21.3) 434 (23.9) 26 (1.3) 227 (12.6) 254 (15.2)
WHODAS-12 – M V 1 1 1 5 1 29 63 1 24 9
Mean (SD) 9.69 (14.2) 13.91 (17.3) 9.36 (14.3) 9.18 (13.8) 8.59 (15.3) 5.30 (12.0) 17.44 (17.2) 12.13 (16.6)
Mean (SD) omitting zeros 16.55 (15.2) 21.11 (17.3) 15.91 (15.7) 16.18 (14.8) 18.03 (17.9) 18.39 (16.1) 22.19 (16.4) 21.33 (17.0)
MV, missing values; NPI-Q severity: total severity in neuro-psychiatric inventory.
doi:10.1371/journal.pmed.1001170.t001
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remainder in Peru, India, and Dominican Republic, although was
lower in China. The pooled fixed-effect model meta-analytical
estimate indicated a positive association with disability although
there was moderate to high heterogeneity in these associations
between countries. After adjustment aMCI cases were more likely
to have informant-rated anxiety, irritability, and apathy symp-
toms, with no significant between-country heterogeneity. Howev-
er, there was no overall association with informant-rated
depression in pooled estimates although the individual prevalence
ratio was significant in Peru.
The prevalence of aMCI ranged from 0.8% in China to 4.3% in
India, and changed very little after direct standardization for age,
gender, and education level, as displayed in Table 3. Adjusted PRs
(95% CI) from Poisson regression models for independent
associations with age, gender, education, and assets are shown in
Table 4. No pooled associations were found with age or education
but there was a modest association with male gender and fewer
assets. Overall little heterogeneity was found between nations in
these associations.
Discussion
Using data from a large series of cross-sectional surveys applying
standard sampling and measurements, we estimated the commu-
nity prevalence of Mayo Clinic–defined aMCI in six countries in
Latin America, China, and India. To our knowledge this is the first
study to attempt to make direct comparisons of prevalence
estimates of aMCI across diverse cultures and world regions.
Differences in prevalence between countries were marked and
ranged from 0.8% (China) to 4.3% (India), i.e., greater than five-
fold variation. After direct standardization for age, gender, and
education, using the whole population as the reference, these
differences were not markedly attenuated.
Inconsistencies in aMCI prevalence observed between the 10/
66 study centres are likely to be due to components of the aMCI
diagnosis itself. In a cross-cultural context, these support questions
previously raised concerning its conceptual basis [67] and/or
operationalization outside clinical settings [68]. However, aMCI
has been reported to be associated with increased mortality in a
prospective study [12], and differences in aMCI-associated
survival between country sites cannot be excluded as a factor
influencing variation in prevalence. It should be noted that the 10/
66 dementia diagnosis showed much higher sensitivity than the
Diagnostic and Statistical Manual of Mental Disorders IV (DSM-
IV) criteria in both pilot and clinical validation 10/66 studies
[41,61]. Compared to numerous aMCI prevalence reports from
community-based sites in Finland (5.3%) [26], Italy (4.9%) [69],
Japan (4.9%) [32], the US (6%) [30], South Korea (9.7%) [39],
Malaysia (15.4%) [38], and India (6%) [37], both the crude and
adjusted aMCI prevalence reported here are relatively low.
However, the estimates are similar to those reported by the
British MRC CFAS study (2.5%) [15] and to estimates for aMCI
prevalence in community samples from Southern France (3.2%)
[33], the US (3.8%) [25], and Germany (3.1%) [70]. Low aMCI
prevalence in our Latin American sites contrast with the aMCI
prevalence (ranging between 3.8% and 6.3% depending on age)
reported amongst American Caribbean Hispanics [31]. Differen-
Table 2. Association between aMCI and disability (WHODAS-12), and the association between aMCI and neuropsychiatric
symptoms (NPI–Q; depression, anxiety, apathy, and irritability).
Analysis ZINB (95% CI) Adjusted
a PRs (95% CI)
WHODAS-12
a Depression
b Anxiety Apathy Irritability
b
Individual study site estimates
Cuba 0.93 (0.74–1.19) 0.96 (0.23–3.93) 1.74 (0.77–3.94) 1.66 (0.59–4.67) 0.84 (0.44–1.57)
Dominican Republic 1.49 (1.08–2.06) 1.04 (0.47–2.30) 1.75 (1.00–3.05) 1.54 (0.76–3.12) 0.98 (0.52–1.82)
Peru 1.51 (1.17–1.94) 2.14 (1.01–4.54) 1.54 (0.89–2.65) 1.38 (0.57–3.33) 1.28 (0.83–1.96)
Venezuela 0.92 (0.53–1.60) 2.14 (0.47–9.74) 2.49 (1.40–4.42) 3.59 (1.94–6.65) 1.74 (1.06–2.86)
Mexico 1.12 (0.78–1.62) 1.07 (0.35–3.29) 1.59 (0.76–3.31) 0.79 (0.35–1.82) 1.11 (0.73–1.69)
China
c 0.67 (0.45–0.99) NC NC 10.2 (1.40–74.5) 9.90 (2.57–38.0)
India 1.20 (1.03–1.40) 0.69 (0.31–1.53) 0.81 (0.25–2.57) 1.18 (0.13–10.8) 1.27 (0.82–1.98)
Puerto Rico 1.05 (0.87–1.27) 2.60 (0.90–7.54) 1.85 (0.98–3.49) 1.68 (0.65–4.34) 1.04 (0.61–1.76)
Pooled meta-analysis (fixed-effect
method)
d
Combined estimate 1.13 (1.04–1.23) 1.31 (0.91–1.89) 1.75 (1.37–2.25) 1.83 (1.33–2.51) 1.24 (1.03–1.49)
Test for heterogeneity p-value 0.008 0.344 0.753 0.091 0.058
I
2 Higgins (95% CI) 63% (20–83) 11% (0–74) 0% (0–71) 43% (0–75) 49% (0–77)
Association between aMCI and disability is measured by exponentiated coefficients from a zero inflated binomial model and representing the increase in disability
of aMCI participants compared to normal. Zero inflation fitted using age, gender, educational level, number of household assets, depression, arthritis, visual problems,
hearing problems, cough and breathing problems, heart problems, gastrointestinal problems, fainting, limb and skin problems, hypertension and stroke. The
association between aMCI and neuropsychiatric symptomsis measured by the risk ratio from a regression using a Poisson working model and model robust
standard errors, and representing the risk for having the symptom in aMCI participants compared to normal.
aAdjusted for age, gender, and educational level, number of household assets and of physical limiting impairments, psychosis, and stroke.
bDepression and irritability were additionally adjusted for pain. The four NPI–Q symptoms are all associated but in the four models presented in the table we have not
adjusted each of them for the other three.
cChina was not adjusted for psychosis
dThe pooled fixed-effect model meta-analytical estimate for depression and anxiety were done without China.
NC, not calculable due to zero cell sizes.
doi:10.1371/journal.pmed.1001170.t002
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the environment and lifestyle in the increased risk of MCI amongst
Hispanic immigrants in North America cannot be excluded.
Crude aMCI prevalence in India (4.3%) is similar to the figure
described by Das and colleagues in Kolkata [37]. Prevalence in
China was the lowest (0.6%), similar only to that described in the
VITA study in Vienna [27] and markedly lower than that reported
in a recent study from Chongqing (4.5%) [29]. Overall, the results
suggest that there is very little consistency in prevalence of aMCI
across world regions. When considered between studies, this may
well reflect diagnostic issues arising from a lack of specific criteria
for the operationalization of MCI (i.e., cognitive batteries and
specific cut-off scores for impairment) as well as unmeasured
differences and cultural variations potentially relevant for some
components of the aMCI construct (such as subjective memory
impairment, as described below). The objective for the analyses
here was to standardize the assessments as much as possible in
order to gain a clearer idea of international variation. The fact that
substantial heterogeneity remains suggests important variation in
constructs underlying the definition. These will be considered
further below.
Female gender, increased age, lower education, and lower
socioeconomic status are associated with dementia [71] and have
beendescribed inassociationwithMCI[31].In ourstudy,however,
theeffectsofageandeducationonaMCIprevalencewerenegligible
across study sites, with no between-country heterogeneity in this
respect. It is important to bear in mind that age- and education-
standardised normative data were used to define aMCI and the lack
of association supports the robustness of the norms, although for
education, it might also reflect lower variance in the exposure or
weaker underlying associations between education and other risk
factor profiles in these samples. Lower socioeconomic status
remained associated with aMCI and this may be an additional
marker, beyond education, of relevant social disadvantage. The
observed association with male gender contrasts with the higher
reported age-adjusted prevalence of dementia in women compared
to men [71], but could reflect the effect of dementia case exclusion
consistent with Mayo Clinic Study of Aging reports that women
experience a transition from normal cognition directly to dementia
at a later age but more abruptly [20].
As described earlier, a key consideration with aMCI applied as a
construct in international research is its cross-cultural validity. An
advantage of the 10/66 study was that identical measures were
taken and identical algorithms applied for diagnosis across the study
sites and the protocols for cognitive assessments in the 10/66 study
were the result of a long and painstaking process of development
and validation [41]. However, a construct such as subjective
memory impairment is potentially subject to cultural influences and
Table 3. Prevalence of aMCI by country, gender, and age group.
Country
and Gender aMCI Prevalence, % (95% CI)
Crude Prevalence
(95% CI)
Standardized
Prevalence (95%CI)
a
65–69 y 70–74 y 75–80 y 80+y All Age Groups All Age Groups
Cuba (n) 738 739 582 555 1.8 (1.3–2.3) 1.5 (1.0–1.9)
Males 1.5 (0.0–3.0) 1.8 (0.2–3.4) 0.0 (0.0–0.0) 1.7 (20.2 to 3.6) — —
Females 2.7 (1.3–4.2) 2.6 (1.1–4.0) 1.6 (0.3–2.9) 0.8 (20.1 to 1.7) — —
Dominican
Rep. (n)
511 483 345 428 1.4 (0.9–2.0) 1.3 (0.7–1.8)
Males 1.7 (20.2 to 3.6) 2.2 (0.0–4.4) 2.7 (20.4 to 5.7) 2.9 (0.1–5.7) — —
Females 0.9 (20.1 to 1.9) 1.7 (0.2–3.1) 0.4 (20.4 to 1.3) 0.7 (20.3 to 1.7) — —
Peru (n) 538 475 368 386 3.1 (2.3–3.9) 2.6 (1.9–3.3)
Males 5.4 (2.1–8.6) 2.7 (0.3–5.1) 2.1 (20.3 to 4.5) 4.4 (1.4–7.4) — —
Females 2.3 (0.7–3.8) 1.7 (0.2–3.2) 3.6 (1.1–6.0) 3.4 (0.9–5.9) — —
Venezuela (n) 813 450 320 236 1.2 (0.7–1.7) 1.0 (0.7–1.4)
Males 1.3 (0.0–2.6) 0.0 (0.0–0.0) 2.6 (20.3 to 5.5) 0.0 (0.0–0.0) — —
Females 1.6 (0.5–2.7) 1.4 (0.0–2.9) 1.5 (20.2 to 3.1) 0.0 (0.0–0.0) — —
Mexico (n) 537 552 384 348 3.2 (2.4–4.1) 2.8 (2.0–3.6)
Males 3.7 (0.8–6.7) 4.3 (1.5–7.0) 5.1 (1.6–8.6) 4.0 (0.8–7.2) — —
Females 1.3 (0.2–2.5) 4.1 (2.0–6.2) 3.9 (1.4–6.5) 1.0 (20.4 to 2.4) — —
China (n) 683 634 417 280 0.8 (0.4–1.2) 0.6 (0.3–0.9)
Males 1.0 (20.1 to 2.1) 0.4 (20.3 to 1.1) 1.7 (20.2 to 3.6) 0.0 (0.0–0.0) — —
Females 1.3 (0.2–2.4) 0.6 (20.2 to 1.4) 0.8 (20.3 to 2.0) 0.7 (20.6 to 2.0) — —
India (n) 703 604 290 201 4.3 (3.3–5.2) 4.6 (3.7–5.4)
Males 7.0 (4.1–9.9) 3.8 (1.5–6.1) 4.8 (1.3–8.3) 1.0 (21.0 to 2.9) — —
Females 3.3 (1.5–5.0) 4.4 (2.2–6.6) 5.6 (1.8–9.5) 1.1 (21.1 to 3.2) — —
Puerto Rico (n) 398 439 436 492 3.9 (3.0–4.8) 3.0 (2.2–3.8)
Males 3.9 (0.1–7.8) 5.5 (1.7–9.2) 4.1 (0.8–7.3) 5.5 (2.2–8.9) — —
Females 4.4 (2.1–6.8) 3.4 (1.3–5.5) 3.5 (1.3–5.6) 2.3 (0.6–3.9) — —
aDirect standardization for age gender and educational level using the whole sample as the standard population.
doi:10.1371/journal.pmed.1001170.t003
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people with objectively lower performance on cognitive assessments
may be more or less likely to admit to memory difficulties. Since this
is a component of the most commonly used definitions of aMCI/
MCI, these cultural variations may be reflected in differing
prevalences. However, despite the differences in prevalences of
aMCI between sites, associations with disability were relatively
consistent, providing support for the cross-cultural applicability of
the aMCI construct. They did not suggest, for example, that only
more severe forms of aMCI were being identified in China where
prevalence was lowest, compared to India where it was highest
(particularly since disability was lower rather than higher in China
in those with aMCI compared to the remainder of the sample).
Associations between aMCI and disability should be viewed with
caution since activities of daily living impairment is an exclusion
criterion for the former. Lower likelihood of reporting difficulties in
China would be unlikely to account for the negative association
observed between aMCI and disability in that site because under-
reporting would have to be differential between those with/without
aMCI.Thereisverylimitedevidencefrompopulation-basedstudies
on the occurrence and characteristics of neuropsychiatric symptoms
that may accompany MCI [18]. While we did not find any
association between aMCI and depressive symptoms, our findings
of a significant association between aMCI and anxiety, apathy, and
irritability are largely consistent with those from the Cardiovascular
Health Study and the Mayo Clinic longitudinal study on aging in
the US [72,73], the Kungsholmen study in Sweden [74], and a
small study from Thailand [75]. However, it should be borne in
mind that individual behavioural/psychological symptoms were not
mutually adjusted as outcomes and the independence of observed
associations in Table 2 cannot be assumed.
Strengths of the study include the very large sample size and the
wide range of populations sampled in terms of culture, economy,
and population characteristics. Moreover, internal validity was
maintained through rigorously prevalidated and standardised
measurements applied consistently between countries in addition
to common algorithms used to define aMCI. There are some
limitations. The samples were drawn from specific geographic
catchment areas and cannot be assumed to be representative of the
source nation/site. No attempt was made to differentiate urban
and rural status in this analysis because not all sites recruited from
both settings. The study was cross-sectional in design and the
impact of survival cannot be evaluated. Furthermore, within the
aMCI category, participants who had developed this late in life
could not be distinguished from those for whom it was a stable
lifetime trait. Finally, aMCI diagnosis was determined without
clinical judgement, which is difficult to obtain in large population-
based studies and unfeasible in most of our study sites. Although
aMCI was originally derived as a diagnosis for secondary or
tertiary care clinical settings, it is being increasingly applied in
epidemiological research and data from community samples is an
important supplement, particularly if future community-level
interventions are planned to prevent progression to dementia.
Our analysis here is intended to extend this particular evidence
base. Follow-up is currently underway in most 10/66 sites, which
will provide further data on predictive validity.
This is one of the first studies, to our knowledge, to investigate
the prevalence of aMCI in LAMICs, where the large majority of
older people and people with dementia currently live [3,4].
Longitudinal data are needed to clarify further the predictive
validity of the aMCI case-definition applied here and to evaluate
the extent to which it can be applied as a risk marker for further
cognitive decline or dementia. In addition, further evaluation is
needed of the associations with disability and neuropsychiatric
symptoms since our findings do suggest higher than expected
comorbidity and there are large absolute numbers of older people
with aMCI in these rapidly ageing and populous world regions.
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Analysis Adjusted PRs (95% CI)
a
Age Gender Education Assets
(Per Year Increment) (Males Versus Females) (More Versus Less Years) (More Versus Less)
Individual study site estimates
Cuba 0.97 (0.92–1.02) 0.63 (0.33–1.21) 0.95 (0.72–1.24) 1.52 (1.00–2.30)
Dominican Republic 1.03 (0.97–1.09) 2.25 (1.04–4.86) 1.27 (0.83–1.96) 0.82 (0.63–1.06)
Peru 1.03 (0.99–1.07) 1.29 (0.75–2.22) 1.08 (0.82–1.42) 0.81 (0.64–1.03)
Venezuela 0.95 (0.88–1.02) 0.79 (0.33–1.90) 0.91 (0.55–1.52) 0.97 (0.83–1.14)
Mexico 1.01 (0.97–1.04) 1.57 (0.94–2.60) 1.24 (0.95–1.61) 0.81 (0.69–0.95)
China 0.97 (0.88–1.06) 1.00 (0.40–2.51) 0.86 (0.64–1.15) 0.80 (0.50–1.27)
India 0.97 (0.94–1.01) 1.19 (0.74–1.93) 1.14 (0.89–1.47) 0.85 (0.72–0.99)
Puerto Rico 0.99 (0.95–1.02) 1.46 (0.91–2.33) 1.04 (0.86–1.26) 0.94 (0.70–1.27)
Pooled meta-analysis (fixed-effect
method)
Combined estimate 0.99 (0.98–1.01) 1.25 (1.01–1.54) 1.06 (0.96–1.16) 0.88 (0.82–0.95)
Test for heterogeneity 0.209 0.25 0.619 0.168
Higgins (95% CI) 27% (0–67) 23% (0–64) 0% (0–68) 33% (0–70)
aMutually adjusted for age, educational level, gender, and number of assets as appropriate.
doi:10.1371/journal.pmed.1001170.t004
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Background. Currently, more than 35 million people
worldwide have dementia, a group of brain disorders
characterized by an irreversible decline in memory,
problem solving, communication, and other ‘‘cognitive’’
functions. Dementia, the commonest form of which is
Alzheimer’s disease, mainly affects older people and,
because more people than ever are living to a ripe old
age, experts estimate that, by 2050, more than 115 million
people will have dementia. At present, there is no cure for
dementia although drugs can be used to manage some of
the symptoms. Risk factors for dementia include physical
inactivity, infrequent participation in mentally or socially
stimulating activities, and common vascular risk factors such
as high blood pressure, diabetes, and smoking. In addition,
some studies have reported that mild cognitive impairment
(MCI) is associated with an increased risk of dementia. MCI
can be seen as an intermediate state between normal
cognitive aging (becoming increasingly forgetful) and
dementia although many people with MCI never develop
dementia, and some types of MCI can be static or self-
limiting. Individuals with MCI have cognitive problems that
are more severe than those normally seen in people of a
similar age but they have no other symptoms of dementia
and are able to look after themselves. The best studied form
of MCI—amnestic MCI (aMCI)—is characterized by memory
problems such as misplacing things and forgetting
appointments.
Why Was This Study Done? Much of the expected
increase in dementia will occur in low and middle income
countries (LAMICs) because these countries have rapidly
aging populations. Given that aMCI is frequently used to
define groups of people who may be at risk of developing
dementia, it would be useful to know what proportion of
community-dwelling older adults in LAMICs have aMCI (the
prevalence of aMCI). Such information might help
governments plan their future health care and social
support needs. In this cross-sectional, population-based
study, the researchers estimate the prevalence of aMCI in
eight LAMICs using data collected by the 10/66 Dementia
Research Group. They also investigate the association of
aMCI with sociodemographic factors (for example, age,
gender, and education), disability, and neuropsychiatric
symptoms such as anxiety, apathy, irritability, and
depression. A cross-sectional study collects data on a
population at a single time point; the 10/66 Dementia
Research Group is building an evidence base to inform the
development and implementation of policies for improving
the health and social welfare of older people in LAMICs,
particularly people with dementia.
What Did the Researchers Do and Find? In cross-
sectional surveys carried out in six Latin American LAMICS,
China, and India, more than 15,000 elderly individuals
without dementia completed standardized assessments of
their mental and physical health and their cognitive function.
Interviews with relatives and carers provided further details
about the participant’s cognitive decline and about
neuropsychiatric symptoms. The researchers developed an
algorithm (set of formulae) that used the data collected in
these surveys to diagnose aMCI in the study participants.
Finally, they used statistical methods to analyze the
prevalence, distribution, and impact of aMCI in the eight
LAMICs. The researchers report that aMCI was associated
with disability, anxiety, apathy, and irritability but not with
depression and that the prevalence of aMCI ranged from
0.8% in China to 4.3% in India. Other analyses show that,
considered across all eight countries, aMCI was modestly
associated with being male (men had a slightly higher
prevalence of aMCI than women) and with having fewer
assets but was not associated with age or education.
What Do These Findings Mean? These findings suggest
that aMCI, as diagnosed using the algorithm developed by
the researchers, is consistently associated with higher
disability and with neuropsychiatric symptoms in the
LAMICs studied but not with most sociodemographic factors.
Because prevalidated and standardized measurements were
applied consistently in all the countries and a common
algorithmwas used todefineaMCI,these findingsalsosuggest
that the prevalence of aMCI varies markedly among LAMIC
populations and is similar to or slightly lower than the
prevalence most often reported for European and North
American populations. Although longitudinal studies are now
needed toinvestigate the extent towhich aMCI can beused as
risk marker for further cognitive decline and dementia in these
settings,thelargeabsolutenumbersofolderpeoplewithaMCI
in LAMICs revealed here potentially has important implications
for health care and social service planning in these rapidly
aging and populous regions of the world.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001170.
N Alzheimer’s Disease International is the international
federation of Alzheimer associations around the world; it
provides links to individual associations, information about
dementia, and links to three World Alzheimer Reports;
information about the 10/66 Dementia Research Group is
also available on this web site
N The Alzheimer’s Society provides information for patients
and carers about dementia, including information on MCI
and personal stories about living with dementia
N The Alzheimer’s Association also provides information for
patients and carers about dementia and about MCI, and
personal stories about dementia
N A BBC radio program that includes an interview with a man
with MCI is available
N MedlinePlus provides links to further resources about MCI
and dementia (in English and Spanish)
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